Real‐world effectiveness of vedolizumab compared toanti‐TNFagents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observationalVEDOIBD‐study

• DOI: 10.1111/apt.17616
• Publication Date: 2023-06-16T04:43:42Z
• Authors: Bernd Bokemeyer; Sandra Plachta‐Da...; Romina di Giuseppe; Philipp Efken; Wolfgang Mohl; Thomas Krause; Martin Hoffstadt; Robert Ehehalt; Leo Trentmann; Axel Schweitzer; Petra Jessen; Petra Hartmann; Stefan Schreiber
• Keywords: Vedolizumab; Faecal calprotectin

Summary Background This observational real‐world evidence (RWE) study is based on prospectively collected data from the VEDO IBD registry study. Aim To compare effectiveness of vedolizumab and anti‐TNF agents in biologic‐naïve patients with ulcerative colitis (UC) at end induction during maintenance treatment. Methods Between 2017 2020, we enrolled 512 UC starting therapy or an agent 45 centres across Germany. We excluded biologic‐experienced those missing partial Mayo (pMayo) outcomes; this resulted a final sample 314 (182 132 agent). The primary outcome was clinical remission measured using pMayo score; any switch to different biologic considered failure (modified ITT analysis). used propensity score adjustment inverse probability treatment weighting correct for confounding. Results During therapy, relatively low similar vedolizumab‐ anti‐TNF‐treated (23% vs. 30.4%, p = 0.204). However, rates after two years were significantly higher vedolizumab‐treated than treated (43.2% 25.8%, < 0.011). Among vedolzumab, 29% switched other biologics, versus 54% who had received agent. Conclusion After treatment, agents.